CEO Executive AssistantExternal affairs is a critical and often underappreciated dimension of pharmaceutical CEO leadership. Drug pricing, patent protection, regulatory pathways, reimbursement policy, and market access conditions are all profoundly shaped by government policy decisions at the federal, state, and international levels. The pharmaceutical CEO who is absent from these policy conversations concedes ground to competitors and, more importantly, to policymakers who may not fully understand the implications of their decisions for drug development and patient access.
At the same time, the operational dimensions of external affairs, including government relations, policy research, trade association participation, public affairs, and coalition management, are highly delegable to specialized professionals. The challenge for pharma CEOs is knowing where their personal engagement creates irreplaceable value and where professional external affairs staff can operate effectively independently.
This framework gives pharmaceutical CEOs a practical approach to delegating external affairs while maintaining the strategic presence that the policy environment demands.
The Pharmaceutical External Affairs Landscape
Pharmaceutical companies engage with external affairs across several distinct domains, each with different CEO involvement requirements.
Federal legislative affairs. Congressional action on drug pricing, patent extension, importation, and FDA authorization shapes the entire pharmaceutical industry’s operating environment. Pharmaceutical companies engage in this landscape through direct lobbying, trade association participation, grassroots advocacy, and CEO-level engagement with members of Congress.
Federal regulatory affairs. FDA policy, including guidance documents, advisory committee processes, and agency leadership priorities, directly affects development and approval timelines. Maintaining a constructive working relationship with FDA leadership is a strategic priority.
State policy engagement. Drug pricing policies, pharmacy benefit manager regulation, and Medicaid formulary decisions at the state level collectively affect market access and revenue for most pharmaceutical products. State policy engagement requires both national coordination and state-specific engagement.
International policy. For companies with significant international operations, engagement with regulatory authorities in the EU, Japan, China, and other major markets, as well as participation in international policy forums like the ICH, requires ongoing external affairs management.
Trade association leadership. PhRMA, BIO, and other trade associations are primary vehicles for collective industry advocacy. CEO participation in trade association governance and positioning is a significant external affairs function.
Public affairs and media relations. Pharmaceutical companies operate in a high-scrutiny public environment where media coverage and public perception directly affect legislative and regulatory outcomes. Managing the company’s public narrative is a continuous external affairs function.
The CEO’s Non-Delegable External Affairs Roles
The CEO’s personal engagement in external affairs is most valuable in five situations.
Senior government leader relationships. Relationships with congressional leadership, committee chairs with jurisdiction over pharmaceutical matters, FDA commissioners and center directors, and HHS leadership belong at the CEO level. These relationships, built over time, provide access and influence that no staff member can fully provide.
High-stakes policy moments. When a major legislative vote on drug pricing is approaching, when a significant regulatory policy change is under consideration, or when a political crisis affecting the industry requires rapid senior leadership response, the CEO must be personally engaged.
Trade association governance. When the CEO serves in a leadership role in PhRMA, BIO, or another trade association, board meetings, executive committee activities, and governance decisions require personal participation.
Public testimony and Congressional appearances. When the CEO testifies before a Congressional committee or participates in a White House forum, their personal preparation and presence are essential. These moments shape public perceptions of the company and industry.
Major public affairs moments. When a major drug pricing announcement, a significant approval, or a corporate decision with broad public health implications requires CEO-level public communication, the CEO must be directly engaged in communications strategy and execution.
Building the External Affairs Delegation Infrastructure
A well-organized external affairs function handles everything below the CEO’s highest-value engagements independently.
Vice President of Government Relations or External Affairs. This senior leader should own the day-to-day management of the company’s external affairs agenda: managing the government relations team, coordinating with trade associations, overseeing state policy engagement, directing public affairs strategy, and keeping the CEO informed of significant developments that require attention.
Federal government relations team. Lobbyists and government relations professionals who manage ongoing congressional and federal agency relationships should own the working relationships with congressional staff, agency officials, and White House staff. The CEO engages at the leadership level; staff manage the operational relationships.
State government relations. A state government relations function or network of contract state lobbyists should manage state-level policy engagement, with a central coordinator ensuring alignment with federal strategy and company positions.
Policy research function. A policy research team should monitor legislative and regulatory developments, analyze policy proposals, develop company policy positions, and produce briefing materials that keep the CEO and senior leaders informed and prepared for external affairs engagements.
Trade association coordination. A trade association liaison or the VP of external affairs should own the operational coordination with trade associations: managing the company’s participation in working groups, tracking association activities, and ensuring that the company’s positions are represented effectively.
For a broader framework on pharma CEO delegation across functions, see our resource on pharma CEO guide.
CEO Preparation for External Affairs Engagements
The external affairs team’s most important support function for the CEO is preparation. A CEO who walks into a congressional meeting or a media interview without thorough preparation is wasting relationship capital.
Before every significant external affairs engagement, the external affairs team should prepare a comprehensive briefing package including: background on the government official or journalist, the company’s relationship history with them, the key policy issues relevant to the meeting, the company’s positions on those issues, anticipated questions or concerns, and recommended talking points.
The CEO reviews these briefings, engages with staff on strategy, and participates in practice sessions for high-stakes engagements such as testimony or major media interviews. Staff manage the logistics of every engagement: scheduling, transportation, materials, follow-up, and relationship tracking after the meeting.
Managing Trade Association Relationships
Trade association participation is one of the most complex dimensions of pharmaceutical external affairs. Associations advocate for collective industry positions that may not perfectly align with any individual company’s interests, and managing this tension requires ongoing strategic attention.
The CEO should engage with trade association governance at the board and executive committee level, participating in decisions about association priorities, strategy, and positions. The external affairs team manages the operational dimensions of trade association participation: attending working group meetings, coordinating the company’s internal review of association positions, and representing the company in association processes that do not require CEO-level participation.
When association positions on priority issues diverge from the company’s interests, the CEO may need to engage personally with association leadership to advocate for the company’s perspective. Staff document and track these advocacy efforts.
State Policy Engagement Strategy
State-level drug pricing policies have become increasingly significant for pharmaceutical companies as states have pursued independent initiatives to address drug costs. Managing state policy engagement requires both national strategy coordination and state-specific expertise.
A state government relations director should own the state policy engagement function: monitoring state legislative activity, coordinating the network of state contract lobbyists, developing state-specific policy positions, and managing the company’s engagement in state regulatory processes. The CEO engages with governors, state legislators, or state health officials only for the most strategically important relationships or policy moments.
International External Affairs
For companies with significant international operations, engagement with regulatory authorities in key markets outside the US requires a parallel external affairs infrastructure.
A head of international affairs or regional external affairs leaders in the EU, Japan, and other significant markets should manage the international policy engagement function. The CEO engages with international policy at the level of meetings with senior regulatory or government leaders in key markets and at international industry forums.
Participation in ICH processes, engagement with EMA leadership, and relationships with MHLW in Japan are examples of international external affairs activities that may warrant CEO-level engagement. The operational dimensions of international external affairs belong with regional teams.
Crisis Communications and External Affairs
When a pharmaceutical company faces a crisis that requires public external affairs response, the CEO’s personal communications are often essential. Product safety issues, major clinical trial failures, drug pricing controversies, and regulatory enforcement actions can all trigger external affairs crises.
A crisis communications protocol that integrates external affairs, communications, legal, and regulatory functions should be in place before a crisis occurs. The CEO leads the organizational response and is the primary public voice in major crises. The external affairs and communications teams manage media relations logistics, draft statements, coordinate government communications, and support the CEO’s public engagement.
According to McKinsey and Company, pharmaceutical companies that invest in robust external affairs functions with strong CEO partnership achieve significantly better policy outcomes than those with under-resourced external affairs capabilities.
Measuring External Affairs Effectiveness
External affairs is a function where outcomes are often indirect and long-term. But proxy measures can give the CEO and board visibility into external affairs performance without requiring deep operational engagement.
The external affairs team should report regularly on: key legislative and regulatory developments and the company’s position relative to desired outcomes, the status of priority government relationships, trade association progress on priority positions, state policy developments affecting the company’s market access, and media coverage trends.
The CEO uses these reports to assess the effectiveness of the external affairs function and to identify where personal engagement is most needed. The external affairs leadership uses them to plan and prioritize their team’s activities.
The Long-Term External Affairs Investment
Pharmaceutical external affairs is a long-term relationship business. The congressional relationships, FDA connections, and trade association leadership positions that matter most are built over years, not months. Companies that invest consistently in these relationships, through CEO-level engagement and strong professional external affairs teams, are positioned to protect and advance their interests more effectively when policy moments require it.
The pharma CEO who invests in a strong external affairs function and maintains strategic personal engagement in the most important policy relationships is not just managing a compliance or communications function. They are shaping the policy environment in which their company’s products will be developed, approved, and accessed by patients. That is a mission-critical investment that deserves commensurate attention and resourcing.
For guidance on delegating the commercial dimensions of the business alongside external affairs, see our resource on pharma commercial strategy.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.